The largest database of trusted experimental protocols

8 protocols using fviia

1

Extrinsic Coagulation Pathway Activation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The extrinsic coagulation pathway is initiated by tissue factor. Tissue factor activity of SIS was quantified by measuring the ability of SIS to catalyze the conversion of Factor X (FX) to activated Factor X (FXa) in a solution containing activated Factor VII (FVIIa). SIS was incubated with 20nM FVIIa and 200nM FX (Enzyme Research Laboratories) in Hank’s Balanced Salt Solution (HBSS) with Ca2+ and Mg2+ for 1 hour at 37°C. The reaction was quenched with ethylenediaminetetraacetic acid (EDTA, 15 mM), and the concentration of FXa was quantified using the chromogenic substrate Spectrozyme® FXa (American Diagnostica) by measuring absorbance at 405 nm for 20 minutes and comparing to known concentrations of FXa.
+ Open protocol
+ Expand
2

Plasma-Derived and Recombinant Coagulation Factors

Check if the same lab product or an alternative is used in the 5 most similar protocols
FVIII-, FIX-, and FXI-deficient plasmas were from Helena Biosciences UK. FII, FIIa, (human plasma–derived) FVII, FVIIa, FIX, FIXa, FX, FXa, and hirudin (recombinant),were from Enzyme Research Laboratories. FV and FVa (human plasma–derived), corn trypsin inhibitor (CTI, recombinant), and full-length TF (human recombinant) were from Haematologic Technologies Inc. FVIII (Advate, human full-length recombinant) was from Baxter Healthcare. FX chromogenic substrate S-2765 (N-a-Z-D-Arg-Gly-Arg–para-nitro-aniline [pNA]) was from Quadratech Diagnostics. FIX chromogenic substrate CS-51 (CH3SO2-D-CHG-Gly-Arg-pNA) was from Hyphen Biomed, FII chromogenic substrate Spectrozyme (H-D-HHT-Ala-Arg-pNA) was from Axis-Shield, and the FII fluorogenic substrate (Z-Gly-Gly-Arg-AMC) was from Bachem. Anti–human-TFPI goat polyclonal antibody (catalog AF2974) was from R&D Systems. T-cal Thrombinoscope calibrator was from Stago. SAPE, SAPC, SAPS, and 1,2-DSPC were from Avanti Polar Lipids. MeOAVM (2,2’-Azobis[4-methoxy-2,4 dimethyl-valeronitrile]) was from WAKO. All other chemicals and lipsofast membranes were from MilliporeSigma, except N-methyl Benzohydroamic acid (NMBHA), synthesized in-house according to ref. 43 (link). Solvents were from Thermo Fisher Scientific.
+ Open protocol
+ Expand
3

Tissue Factor Activity Assay in Cells and Tumor Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols
1.8 × 104 intact, non-permeabilized cells were washed and incubated with 15 nM FVIIa and 150 nM FX (Enzyme Research Laboratories) at 37˚C for 15 minutes. Subsequently, CaCl2 was added to initiate FXa generation. The samples were incubated for another 15 minutes at 37˚C after which time the reaction was halted by the addition of EDTA-Bicine. Pefachrome FXa (5-Diagnostics P085–06-25) was then added and the OD405 recorded every 5 minutes for 1 hour using a VersaMax microplate reader (Molecular Devices). To assess TF activity in tumor specimens, frozen tissue was crushed in liquid nitrogen and then added to a buffer (10 mM HEPES, pH 7.4, 140 mM NaCl) containing 2 µM of E-64. Lysates were prepared via freeze-thaw on dry ice, and homogenized by passing through a 28G needle. Protein concentration was determined using BCA. 30 µg total protein per sample were used to perform two-step FXa assay as above.
+ Open protocol
+ Expand
4

Chromogenic Assays for Coagulation Factors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Factors IXa, Xa, VIIa, XIa, and thrombin amidolytic activity were assayed by incubating purified enzymes with cystamine (0.2–200 mM, in a 2-fold serial dilution) and measuring the cleavage rate of chromogenic substrates (Pefachrome FIXa, FXa, FVIIa, FXa, and TG, respectively [Enzyme Research Laboratories, South Bend, IN, USA]). The Ki was determined by first calculating the apparent Ki (Ki, app) using the equation v(V0)-1 = 1-[I](Ki, app+[I])-1. Since the inhibitor and substrate are in competition, the true Ki was then calculated using the equation Ki = Ki, app (Km([S]+Km)-1).
+ Open protocol
+ Expand
5

Recombinant FVIII Coagulation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Recombinant FVIII (Kogenate™) was a generous gift from Dr. Lisa Regan of Bayer Corporation (Berkeley, CA). Dioleoyl phospholipids [Phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS)] were purchased from Avanti Polar Lipids (Alabaster, AL). The reagents α-thrombin, FVIIa, FIXaβ, FX, and FXa (Enzyme Research Laboratories, South Bend, IN), hirudin (DiaPharma, West Chester, OH), the chromogenic FXa substrate, Pefachrome Xa (Pefa-5523, CH3OCO-D-CHA-Gly-Arg-pNA·AcOH; Centerchem Inc. Norwalk CT), Enhanced Chemifluorescence reagent (GE Healthcare Bioscience, Piscataway, NJ), recombinant human tissue factor (rTF: Innovin, Dade Behring, Deerfield, IL), flourogenic substrate (Z-Gly-Gly-Arg-AMC: Calbiochem, San Diego, CA), and thrombin calibrator (Diagnostica Stago, Parsippany, NJ) were purchased from the indicated vendors.
+ Open protocol
+ Expand
6

Measuring Circulating Tissue Factor-Bearing Microparticles

Check if the same lab product or an alternative is used in the 5 most similar protocols
Circulating TF-MP procoagulant activity was measured using the chromogenic reporter substrate (Pefachrome FXa 8595, Enzyme Research Laboratories, South Bend, IN). Briefly, 250 µL of human platelet free plasma was diluted with 1 mL of HBSA (137 mM NaCl, 5.4mM KCl, 5.6 mM Glucose, 10 mM HEPES, 0.1% bovine serum albumin, pH 7.4) and centrifuged at 21,000 × g for 15 min at 4°C to pellet MPs. Pelleted MPs were washed once with HBSA and resuspended in 160 µL HBSA. 50 µL of MP suspensions were then incubated in 50µL of HBSA containing 73.2 nM FX (Enzyme Research Laboratories), 2.4 nM FVIIa (Enzyme Research Laboratories), and 10 mM CaCl2 for 2 hours at 37°C in a 96-well plate. The reaction was stopped with 25 µL of HBSA containing 25 mM EDTA. Then, 25 µL of FXa substrate (Pefachrome FXa, 4.0 mM) was added to the reaction and incubated for 15 min at 37°C, and OD 405 nm recorded using Synergy 2 Multi-Mode Microplate Reader (BioTek). To calculate TF-MP procoagulant activity, a standard curve was generated using recombinant relipidated TF (0–30 pg/mL, Haematologic Technologies, Essex Junction, VT).
+ Open protocol
+ Expand
7

Quantifying Cell Surface TF-fVIIa Activity

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell surface TF-fVIIa activity was measured by modification of previously described procedures [4] . MDA-MB-231 cells (5 × 10 4 ) were incubated with the compound inhibitors (100 µM) diluted in the reaction buffer (100 µL; HEPES-buffered saline (HBS) pH 7.4, containing 1% (w/v) bovine serum albumin (BSA) and 5 mM CaCl 2 ) for 60 min. The cells were washed and incubated with fVIIa (20 nM; Enzyme Research Labs, Swansea, UK) in the reaction buffer for an additional 10 min and then supplemented with fX (100 nM), together with fXa substrate (0.2 mM; Hyphen) diluted in the same buffer (100 µL). The samples were incubated for 60 min to develop the colour. Aliquots (150 µL) were then transferred to a 96-well plate containing 2% (v/v) acetic acid (50 µL) and the absorptions measured immediately at 405 nm. The amount of fXa generated was determined using a standard curve prepared using fXa (Enzyme Research Labs, Swansea, UK). To confirm the cell surface TF activity, cells were pre-incubated with the inhibitory anti-TF antibody HTF1 (40 µg/mL; eBioscience/Thermo Scientific, Warrington, UK) prior to the addition of fVIIa.
+ Open protocol
+ Expand
8

Quantifying Cell Surface TF-fVIIa Activity

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell surface TF-fVIIa activity was measured by modification of previously described procedures [3 (link),24 (link),31 (link)]. Cells (5 × 104) were seeded out into 48-well plates and transfected with the appropriate wild-type or mutant TF plasmids, as shown in Table 1. The cells were washed with phosphate-buffered saline (PBS) pH 7.4 and then pre-adapted to serum-free medium. The cells were incubated with PAR2-AP for up to 60 min and then washed and incubated with fVIIa (20 nM; Enzyme Research Labs, Swansea, UK) in HEPES-buffered saline (HBS) pH 7.4, containing 1% (w/v) bovine serum albumin (BSA) and 5 mM CaCl2 (100 µL) for an additional 10 min. Finally, the samples were supplemented with fX (100 nM) together with fXa substrate (0.2 mM; Hyphen) diluted in the same buffer (100 µL). The samples were incubated for 60 min to develop the colour. Aliquots (150 µL) were then transferred to a 96-well plate containing 2% (v/v) acetic acid (50 µL) and the absorptions were measured immediately at 405 nm. The amount of fXa generated was determined using a standard curve prepared using fXa (Enzyme Research Labs). To inhibit cell surface TF activity, cells were pre-incubated with the inhibitory anti-TF antibody HTF1 (40 µg/mL; eBioscience/Thermo Scientific, Warrington, UK) prior to the addition of fVIIa [15 (link)].
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!